RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease
Trial details
- Registry ID
- NCT04616924
- Drugs studied
- RHB-204
TrialRedline tracks 4 clinical trials sponsored by RedHill Biopharma Limited: 1 Phase 3, 2 Phase 2 / 3, 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex DiseaseNCT04616924 | RHB-204 | Terminated | 2023-08-28Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 PneumoniaNCT04467840 | Opaganib | Completed | 2021-07-18Actual |
| Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 DiseaseNCT04723537 | Part A: Upamostat 200 mg, Part A: Upamostat 400 mg, Part B: Upamostat 200 or 400 mg | Terminated | 2021-12-28Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced CholangiocarcinomaNCT03377179 | ABC294640, Hydroxychloroquine Sulfate 200 MG | Completed | 2022-06-21Actual |
Names as written in the registry records.